Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. - Wikidata - awgldk - TriplyDB

Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.

Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.

http://www.wikidata.org/entity/Q51989383

about

A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma Lymphoma Immunotherapy: Current Status Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma Active idiotypic vaccination versus control immunotherapy for follicular lymphoma Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses.Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes.An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones.Therapeutic vaccine for lymphoma.Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen Anti-idiotype antibodies in cancer treatment.B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas.CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant.Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier.Active immunotherapy: current state of the art in vaccine approaches for NHL Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity.Hybridoma-Derived Idiotype Vaccine for Lymphoma: Approval Must Wait.Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma.Immunotherapy for B-cell lymphoma: current status and prospective advances Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine.Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.Current trials for frontline therapy of mantle cell lymphoma.Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.

P2860

Q24681501-35C69AD7-318F-4621-9BAD-B5D0141F692E Q26782902-3D98D17D-93D6-46FC-85DD-758130E2C4B3 Q30419228-6A76807F-2AB0-4C8A-8177-B4BCD9AD4153 Q33691505-DAB701F6-F5EB-4109-9815-931DC787508C Q34038839-DD4338DD-7592-4352-AE8C-F4B2A0115D74 Q34075717-039FB94F-AC07-45A8-B2FF-C8FBE893A3A1 Q34097414-270D9431-B827-45E1-B7FD-BE921AFECFBB Q34194680-E0B4EFF8-E655-4B66-886A-F177F7D4C076 Q35113388-33DF442A-BC4A-41C2-9ED2-E8E2D70B782F Q35114545-41C2DC09-3DF9-446A-B990-88B06CBC2936 Q35144751-CAB08DA0-DB3F-40C3-A09D-081DF33B9205 Q35990678-3B89A76D-159C-47D9-995D-599EC9D5E69A Q36194235-DF650436-EBA5-47DA-A58F-8B338F94C895 Q36312922-2F8F80DA-D2C6-4D77-9AC9-BCFAADEC3F66 Q36491970-A34718DF-0885-46F2-A6D7-861C20766AE7 Q36746586-63A6385D-6D10-4895-B99B-6E92C87B5BD0 Q36788328-8BB0D00E-5C3A-4E98-8E7D-F974ED3DE26C Q36832098-673DB591-0759-415F-9B39-F85D8F16DE83 Q37069120-20B56D0B-21C6-4CCA-B572-2800E7C47D1D Q37142202-3F914AB0-F989-4325-A4A4-C6C17C6EC080 Q37144907-0A458E32-F33D-46AC-BEE3-4628E7615977 Q37222108-F802C409-A4D9-4849-960B-CBC29DEAA553 Q37260574-C969FC82-C288-4429-8B1E-85B80F454993 Q37773301-3DBB571A-0DB6-48BE-BB12-3D83491F0259 Q37819809-BFA3FED3-A160-4EEA-B883-DD46D59D7C78 Q38030484-6494E708-1172-435C-A0CE-B549F4DB80DB Q38532002-BE290E45-70D4-4103-8E11-61EF1C021BD2 Q38810148-CC00E003-5D46-4814-AA5D-542A0F93B612 Q38974216-24EB891D-D062-428D-B1BA-26E89AFC7A5E Q39250390-FB19789C-2D03-4AED-98E6-527BF3D42A80 Q41831989-AA585876-1A01-4FB2-A988-D12DFB0781F9 Q42032055-E0FB143E-07DE-434D-90AE-37D4E1CAEFC5 Q42063919-2C80A13D-4CB0-47EF-A6E8-990FE02149D5 Q43231874-8FAC4BC1-CC5D-491B-9135-07BD977F20DA Q46398502-66DB9D4E-E596-461F-A1BE-60C3B985D0CE Q49279565-7C5CCC68-9547-4A72-8E24-2D8A17BA6DB1 Q49935482-797BA2DE-5401-4DF4-A06F-E45B8E0E2D6B Q55610546-7DB1FC65-71C9-4400-868F-09D7BEBB5BD8

P2860

Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.

http://www.wikidata.org/entity/Q51989383

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Vaccine-induced tumor-specific ...... etion in mantle cell lymphoma.

@en

Vaccine-induced tumor-specific ...... etion in mantle cell lymphoma.

@nl

type

label

Vaccine-induced tumor-specific ...... etion in mantle cell lymphoma.

@en

Vaccine-induced tumor-specific ...... etion in mantle cell lymphoma.

@nl

prefLabel

Vaccine-induced tumor-specific ...... etion in mantle cell lymphoma.

@en

Vaccine-induced tumor-specific ...... etion in mantle cell lymphoma.

@nl

P1433

Q51989383-1A668C1C-9055-421B-8EC2-9B485E446969

P1476

Q51989383-C4690A3F-FAB9-481D-88FA-502D60CEEE2A

P2093

Q51989383-2F204799-BDEC-4596-A9CF-193B806E0AA0

Q51989383-444F50C8-C5DF-4D79-818E-BE0FF6C5335B

Q51989383-50F091D7-7399-4149-A2B1-05086ECE83A9

Q51989383-54DD2724-B0B9-401C-80BF-1ED0650D97B3

Q51989383-642D0E20-1125-426A-A14D-DDD593E11AE6

Q51989383-7A4E0059-BAAD-4DE1-856A-AFC9F613B433

Q51989383-83525759-C390-43B5-805F-31FDD5B54BB3

Q51989383-AC1EA18E-F91E-4EDB-99B7-09C1CC203601

Q51989383-AE284CCE-76E1-4A02-AB0F-9C1DE16A78BA

Q51989383-B0BB8A65-227C-43EC-835E-12472F5D5197

P2860

Q51989383-12E9293F-D308-4930-A8A4-AB1F685CD98C

Q51989383-1346A14B-005A-4673-A3AF-4CD1B6DAB5C5

Q51989383-136B5D8F-2ABC-48E8-8AA7-4A26932576F8

Q51989383-27032324-9BA3-4AB8-A7AE-CE442FBF3D12

Q51989383-2C0E4E86-DED1-4043-A52B-F5AE8FE31D36

Q51989383-40258A4E-6186-44C0-B770-12AA3EB8BED9

Q51989383-4BD28F27-64B0-4C5B-9323-8BD18BC5EC53

Q51989383-557CBA0A-B6B3-4C3F-9748-6482FEB43011

Q51989383-7B50336B-2BEA-437A-AC59-015923B9BFF6

Q51989383-8AA5569B-D4E3-4B4B-9A39-F90AA9BE8D3B

P2888

Q51989383-BC803DBD-182E-45D4-9218-B8A1A761983C

P304

Q51989383-0D0F8D6E-A793-4475-B0C9-9D2B441C53F3

P31

Q51989383-DEDC1282-19FE-453B-81C1-FD4889470A31

P356

Q51989383-35192DDA-F32C-4E87-8212-7CD49B10D979

P407

Q51989383-7877EA65-BA7B-46B6-A6DE-ECF63E03FA19

P433

Q51989383-939B6D4B-D004-4AC9-959A-4DAD7DE80FF0

P478

Q51989383-5A255D6B-1AE4-49B7-AB48-E354F17432E5

P577

Q51989383-15ADB03B-4178-4277-A91A-F0EEFBEE9B18

P5875

Q51989383-C70E9155-BE79-4108-9700-9DF69CE97A22

P698

Q51989383-A1DDCB42-D263-42D5-879D-FCC5A7922C8A

P356

P1433

Nature Medicine

P1476

Vaccine-induced tumor-specific ...... etion in mantle cell lymphoma.

@en

P2093

Carol B Kobrin

http://www.w3.org/2001/XMLSchema#string

Craig W Reynolds

http://www.w3.org/2001/XMLSchema#string

Elaine S Jaffe

http://www.w3.org/2001/XMLSchema#string

Fran Hakim

http://www.w3.org/2001/XMLSchema#string

John E Janik

http://www.w3.org/2001/XMLSchema#string

Kieron Dunleavy

http://www.w3.org/2001/XMLSchema#string

Larry W Kwak

http://www.w3.org/2001/XMLSchema#string

Linda Harvey

http://www.w3.org/2001/XMLSchema#string

Maryalice Stetler-Stevenson

http://www.w3.org/2001/XMLSchema#string

Robin Pennington

http://www.w3.org/2001/XMLSchema#string

P2860

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

Effective B cell depletion with rituximab in the treatment of autoimmune diseases.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

Development of effective immunotherapy for the treatment of patients with cancer.

Antigen-induced regulatory T cells.

Non-Hodgkin lymphoma: an update.

Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens.

B cells directly tolerize CD8(+) T cells.

P2888

P304

986-991

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM1290

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7645188

http://www.w3.org/2001/XMLSchema#string

P698

16116429

http://www.w3.org/2001/XMLSchema#string